Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
ID: 339446Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/339446

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-131.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes." This initiative aims to support innovative projects that integrate advanced imaging technologies, biomarkers, and multi-omic data to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic sensitivity and specificity. The program is crucial for addressing diagnostic uncertainties in clinical settings and aims to reduce overdiagnosis and false results in cancer screenings. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with project budgets reflecting actual needs over a maximum duration of five years. Interested parties should submit their applications by September 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. For more details, visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-131.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-131.html
    The Department of Health and Human Services is soliciting proposals through the National Institutes of Health (NIH) for innovative projects aimed at improving cancer detection. This Funding Opportunity Announcement (FOA), titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes," seeks applications focusing on the integration of imaging technologies, biomarkers, and multi-omic data. The initiative aims to enhance diagnostic sensitivity and specificity to reduce overdiagnosis and false results in cancer screenings. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and federal entities, with a project budget reflecting real needs over a maximum of five years. The anticipated outcomes include facilitating collaboration among research teams, improving methodologies for identifying aggressive cancer, and leveraging advancements in artificial intelligence and data integration for clinical decision-making. The application process requires compliance with NIH guidelines and emphasizes collaboration among diverse expertise in imaging and biomarker research. All funded projects will participate in the Consortium for Imaging and Biomarkers (CIB), aiming to collectively advance the field of cancer research. Key deadlines are set for submission, with a program expiration date of September 8, 2025.
    Similar Opportunities
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), is offering a funding opportunity titled "Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis" under the R01 Research Project Grant program. This initiative aims to support research projects that implement early phase clinical trials (Phases 0, I, and II) focused on cancer-targeted diagnostic and therapeutic interventions, aligning with the NCI's mission to advance cancer research. Eligible applicants include a diverse range of organizations such as colleges, nonprofits, and governmental entities, with a maximum project budget of $499,999 in direct costs per year and an award period not exceeding five years. Interested parties should note that applications are due by January 7, 2027, and can seek further information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html.
    Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer inflammation through innovative molecular imaging techniques. This initiative encourages applications that leverage in vivo imaging methods to provide deeper insights into the dynamic interactions between inflammation and cancer, moving beyond traditional in vitro approaches. The program seeks multidisciplinary collaborations among cancer biologists and imaging scientists to develop integrated imaging strategies and molecular probes for real-time monitoring of inflammatory responses within the tumor microenvironment. Interested applicants can apply for up to $500,000 annually for a maximum of five years, with the application deadline set for January 8, 2028. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research" through Cooperative Agreements (U01). This initiative aims to advance research in cancer etiology and early detection biomarkers by utilizing the unique biorepository resources from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, which includes pre-diagnostic blood samples and associated clinical data. The research projects must specifically involve PLCO biospecimens and focus on exploring cancer risk factors and early detection biomarkers, with the overarching goal of reducing cancer risk and improving the quality of life for survivors. Interested applicants can find more information and submit their proposals by the closing date of October 8, 2027, and should direct inquiries to grantsinfo@nih.gov for further assistance.
    Forecast to Publish a Funding Opportunity Announcement for Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing the development of informatics technologies for cancer research and management. This initiative seeks applications for the enhancement of emerging informatics technologies that have shown potential in improving data acquisition, analysis, visualization, and interpretation across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The emphasis is on technologies that are unique and have the potential for significant impact, with a requirement for clear development plans, user engagement, and collaboration strategies. While applications are not currently being solicited, interested parties are encouraged to prepare for submission, with the estimated synopsis post date set for August 29, 2025, and a projected award date of July 1, 2026. For further inquiries, potential applicants can contact Juli Klemm, PhD, at juli.klemm@nih.gov or by phone at 202-853-7889.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This funding opportunity aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance the understanding of cancer biology, improve early detection, and address cancer health disparities. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and is particularly interested in projects that have overcome major feasibility gaps, as evidenced by preliminary data, but still require further validation for broader adoption in the research community. The total estimated funding for this program is $4.5 million, with individual awards ranging from $50,000 to $150,000, and a total of nine awards expected. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information. The application deadline is April 10, 2026, with awards anticipated to be made by December 1, 2026.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Forecast to Publish a Funding Opportunity Announcement for Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the sustained development of informatics technologies for cancer research and management. This initiative seeks applications for the continued operation and enhancement of existing informatics resources that facilitate data acquisition, management, analysis, and dissemination across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The emphasis is on maintaining resources that have demonstrated significant impact on cancer research, with a focus on user engagement and support. While applications are not currently being solicited, potential applicants are encouraged to prepare collaborative projects in anticipation of the NOFO, which is expected to be posted on August 29, 2025, with a closing date for submissions on November 21, 2025. For further inquiries, interested parties can contact Dr. Juli Klemm at juli.klemm@gmail.com or by phone at 202-853-7889.